TC Medical(SH:600763) Sou Hu Cai Jing·2025-10-31 12:17Core Viewpoint - Tongce Medical (600763) shows a positive performance with a closing price of 43.45 yuan, up 1.8% as of October 31, 2025, indicating a stable market interest in the company [1]. Financial Performance - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56% [3]. - The net profit attributable to shareholders reached 514 million yuan, up 3.16% year-on-year, while the net profit after deducting non-recurring gains and losses was 509 million yuan, increasing by 3.09% [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 842 million yuan, a year-on-year increase of 2.34%, and a net profit of 192 million yuan, up 2.31% [3]. Market Activity - On October 31, 2025, the net inflow of main funds was 14.46 million yuan, accounting for 4.78% of the total transaction amount, while retail investors experienced a net outflow of 3.39 million yuan, representing 1.12% of the total [1][2]. - Over the past five days, the stock has seen fluctuations in fund flows, with varying levels of net inflow and outflow from different investor categories [2]. Industry Comparison - Tongce Medical's total market capitalization stands at 19.435 billion yuan, ranking 8th in the medical services industry, while its net profit ranks 6th [3]. - The company has a price-to-earnings ratio of 28.39, significantly lower than the industry average of 375.95, indicating a potentially undervalued position [3]. Analyst Ratings - In the last 90 days, 9 institutions have rated the stock, with 7 buy ratings and 2 hold ratings, suggesting a generally positive outlook among analysts [4]. - The average target price set by institutions is 52.01 yuan, indicating potential upside from the current trading price [4].